Abbott, a leading global healthcare company, has unveiled the XIENCE Sierra™ Everolimus Eluting Coronary Stent System in India, marking a significant advancement in cardiac care technology.

Tailored to address blocked coronary arteries, XIENCE Sierra represents the latest innovation in Abbott's renowned XIENCE™ stent family, offering interventional cardiologists a heightened level of precision and safety in managing complex cases, the healthcare company said in a press release.

Percutaneous coronary intervention (PCI), commonly known as coronary angioplasty, is a minimally invasive procedure aimed at restoring blood flow to the heart by widening or unblocking narrowed or obstructed arteries. The introduction of the XIENCE Sierra stent is poised to revolutionize PCI procedures by providing an enhanced stent design, a novel delivery system, and a range of sizes to cater to diverse patient needs.

XIENCE Sierra inherits the specialized coating from its predecessors within the XIENCE family, significantly reducing the risk of arterial re-blockage. With a robust safety record established through extensive clinical trials involving over 120,000 patients, XIENCE stents have demonstrated efficacy in treating challenging lesions and patients with complex conditions.

Tushar Sharma, General Manager of Abbott's vascular business in India & South Asia, emphasized the stent's innovative design and improved deliverability, enabling physicians to navigate and treat even the most intricate lesions with precision and flexibility. Given the rising prevalence of coronary artery disease in India, Abbott's commitment to providing cutting-edge technologies aligns with the imperative to optimize patient outcomes.

Key features of XIENCE Sierra include an expanded range for vessel sizes and high longitudinal strength, ensuring stability and minimizing the risk of deformation during deployment. Its ease of use empowers physicians to tackle challenging anatomies and perform intricate techniques with confidence, enhancing overall procedural efficacy and patient safety.

With cardiovascular diseases accounting for a significant portion of non-communicable disease-related mortality in India, the introduction of XIENCE Sierra underscores Abbott's dedication to addressing the nation's healthcare needs. Alongside next-generation stents, Abbott continues to support physicians with advanced imaging tools and diagnostics, further augmenting the capabilities of interventional cardiologists in delivering optimal care.

As the XIENCE Sierra stent enters the Indian market, it represents a milestone in the ongoing evolution of cardiovascular interventions, promising improved outcomes and enhanced quality of life for patients battling coronary artery disease.